Abstract 2145
Background
The pathological classification of pancreatic neuroendocrine neoplasms (PanNENs) has been revised based on the World Health Organization (WHO) 2017 classification. Well-differentiated PanNENs were previously classified as G1, G2, or G3 according to the Ki-67 labeling index (LI), which shows the cell proliferation ability. Although the Ki67 LI cut-off for G1 and G2 was changed from ≤2% to < 3% from WHO 2010 to 2017, there are few reports on the impact of G2 tumor malignancy associated with this change.
Methods
Patients with PanNENs G1/G2 classified by WHO 2017 Ki-67 LI cut-off who underwent pancreatic resection at our institution between July 1987 and March 2019 were retrospectively analyzed. We excluded patients with synchronous distant metastasis at the time of diagnosis. Their clinicopathological variables were analyzed.
Results
Sixty-two patients (median age: 58 years; range: 18–84 years) were examined. The G1/G2 groups comprised 40/22 and 48/14 patients based on WHO 2010 and 2017 classifications, respectively. Eight patients were reclassified from G2 to G1, two of which were T2 or more based on TNM classification; one patient had lymph node metastasis positivity, and all patients survived without recurrence. Disease recurrence occurred in 4/4 G1/G2 patients according to both WHO 2010 and 2017. G2 patients had shorter 5- and 10-year disease-free survivals (DFSs) than those of G1 patients based on WHO 2010 (90.9% and 90.9% vs. 84.5% and 70.4%, p = 0.179) and significantly shorter DFS based on WHO 2017 (91.9% and 91.9% vs. 78.6% and 58.9%, p = 0.036). The Ki-67 LI cut-off by ROC analysis was 3%, supporting the WHO 2017 classification. In multivariate analysis for DFS, tumor size >25 mm and vascular invasion positivity, but not G2, were risk factors for recurrence. The high-risk group with these factors had significantly worse 5- and 10-year disease-specific survivals (DSSs) compared to the low-risk group (100% and 100% vs. 90.9% and 68.2%, p = 0.045).
Conclusions
Revision of the Ki-67 LI cut-off for PanNENs G1/G2 based on WHO 2017 may be appropriate but G2 is not a risk factor for DFS. Tumor size >25 mm and vascular invasion positivity are potential risk factors. High-risk patients should be closely monitored during follow-up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3330 - Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy
Presenter: Leonora De Boo
Session: Poster Display session 2
Resources:
Abstract
3971 - Unravelling the biological characteristics of MammaPrint extreme risk subgroups
Presenter: Rajith Bhaskaran
Session: Poster Display session 2
Resources:
Abstract
5871 - Residual Cancer burden as a prognostic factor in a large series of Neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes
Presenter: Catalina Falo
Session: Poster Display session 2
Resources:
Abstract
5014 - Clinical validation of CanAssist Breast in a Spanish cohort
Presenter: Manjiri Bakre
Session: Poster Display session 2
Resources:
Abstract
2787 - Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer
Presenter: Peter A. Fasching
Session: Poster Display session 2
Resources:
Abstract
4301 - Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial
Presenter: Gaia Griguolo
Session: Poster Display session 2
Resources:
Abstract
3205 - Frequency of germline mutations in women's cancer susceptibility genes in a large cohort of Chinese breast cancer patients
Presenter: Ning Liao
Session: Poster Display session 2
Resources:
Abstract
4091 - Triple blinded Prospective Study assessing the Impact of Genomics & Artificial Intelligence Watson For Oncology (WFO) on MDT’s Decision of Adjuvant Systemic Therapy for Hormone Receptor Positive Early Breast Carcinoma-
Presenter: Somashekhar Sampige Prasannakumar
Session: Poster Display session 2
Resources:
Abstract
4359 - Prognostic significance of Progesterone Receptor levels in luminal-like Her2- early Breast Cancer patients. A retrospective single Cancer Center analysis.
Presenter: Anna Diana
Session: Poster Display session 2
Resources:
Abstract
1369 - PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis
Presenter: Francesco Schettini
Session: Poster Display session 2
Resources:
Abstract